World Cannabis Landscape.

3 TSX.V:PURE OTC:PRCNF World Cannabis Landscape. The global legal marijuana market is expected to reach USD 146.4 Billion by end of 2025 Grand View Research, Inc. April 2018 MEDICAL MEDICAL & RECREATIONAL

4 TSX.V:PURE OTC:PRCNF Canadian Leadership With A Pure World View Comprised of pharma-industry experts, our team is dedicated to producing the highest quality consistently PURE cannabis products. Our vision is to become the most trusted global brand, while harnessing the therapeutic properties of cannabis in tomorrow s medicines and consumer products.

5 TSX.V:PURE OTC:PRCNF Why Own PURE? Attractive Relative Valuation International Exposure - Production in Canada & Colombia * Exceptional Leadership Team & Advantageous Intellectual Property Fully-Funded Milestones TSX.V: PURE OTC: PRCNF Price: $0.34/share*** PURE expecting total production capacity of 132,000 KG in Canada & Colombia** - GMP grade facilities Canada s first multi-ponic cannabis farm, a patent pending system producing yields several fold greater than traditional operations 2 Licenses*: Flagship Brampton Facility 41,000 sq ft Flagship Colombian Facility - Sativa Nativa S.A.S.* - 28 hectares Market Cap: $50M Issued & outstanding: 148.2M Warrants & options: 34.6M Aggregate PURE production footprint expected to be 904,000 square feet** Patent-pending high-efficiency vertical farm maximizes utility of production footprint Canada - Completed phase 1, phase 2 & 3 expected completion by Q4 2018 and Q1 2019 Fully diluted: 182.8M Avg market cap of Cdn LP: $1.12B Mdn market cap of Cdn LP: $217M * Assumes completion of binding LOI signed with Avicanna Inc, previously announced August 15, 2018 ** Assumes 75% interest in Sativa Nativa S.A.S. *** As of September 4, 2018 Focused on domestic & international distribution - medical clinics, wellness segment, recreational, EU & Latin American exports Branding of PureSinse as primarily Medicinal & Wellness brand for Canadian distribution Seasoned pharma-industry experts and world-renowned specialist in plant genetics, commercial scale indoor, greenhouse horticulture Adapting pharmaceutical technologies to develop unique cannabis formulations for specific use cases Canada - Total 41,000 sq ft. proprietary multi-ponic vertical cultivation facility - expected total funded production capacity of 8,000+ kg per annum Colombia - 100,000 sq ft. GAP greenhouse nearing completion along with 20,000 sq ft. GMP grade greenhouse & extraction facility Colombia - Additional 1,000,000 sq ft. leading state-of-the-art greenhouse anticipated at a fraction of the cost to traditional Canadian producers

6 TSX.V:PURE OTC:PRCNF Flagship Canadian Facility - Brampton Campus The PureSinse facility sits in the heart of an industrial district in Brampton, Ontario, strategically located 10 minutes from the Toronto International Airport and 35 minutes to the downtown core. PHASE 1* Q3 2018 Completed Phase 1 Level 9 Vault Stores $32M in Product Extraction, QA & Microbiology Labs Order Processing & Packaging Shipping & Receiving Security, IT & Admin PHASE 2* Q1 2019 18,000 SQ. FT. 4,000 kg/yr * Automated Controlled Growth Environments Multiple Tiers of Vertical Farming Cultivation Tissue Culture, Cloning, & Mother Rooms Drying, Trimming & Processing Extraction, Processing, & Packaging PHASE 3* Q1 2019 41,000 SQ. FT. 8,000 kg/yr * Vertical Farming Cultivation Cloning, Vegetation & Flowering Scaled Extraction & Distillation Lab Order Processing & Packaging Advanced Analytical R&D Laboratory Continuously evaluating opportunities for additional expansion, both at our current facility and beyond. *Estimated

7 TSX.V:PURE OTC:PRCNF Canada - Secured Inventory - Ready for Sales PureSinse TM Medical and Wellness focused brand, wholly owned subsidiary, PureSinse Inc, licensed to cultivate under the Access to Cannabis for Medical Purposes Regulations ("ACMPR"), anticipates to receive its ACMPR Sales License in Q3/Q4 2018 Completed Phase 1 buildout - Commenced Phase 2 & Phase 3 congruent build-outs with completion expected during Q4 2018 and Q1 2019 respectively Phase 1 ready for Sales Licensing Fully secured inventory - Secured inventory in excess of $1.5M with agreements with Supreme, among other top tier Licensed Producers, pursuing additional long-term supply agreements GMP/ISO Facility + R&D Lab Initiated data collection for European Good Manufacturing Practice ( eugmp") and ISO certifications (eugmp expected H1 2018), along with investment in advanced analytical R&D laboratory for product formulation, derivatives and extracts processing Revenue Generation & Distribution - Customer acquisition, branding, and sales strategy includes partnerships with major Canadian medical clinics, along with the expected inclusion in future provincial product calls nationwide - PURE expects revenue generation to commence shortly upon receipt of Sales License in Q4 2018 Estimated Q4 2018 / Q1 2019 Estimated Q3/Q4 2018 May-Sept 2018 December 2017 Phase 2/3 Facility Expansion Complete Sales License Received Secured Product Inventory ACMPR Cultivation License Received

8 TSX.V:PURE OTC:PRCNF Canada s First Multi-Ponic Cannabis Farm Pure s VP Production is an award-winning plant geneticist and horticulture specialist, with extensive experience growing hundreds of plant varieties and managing commercial-scale grow operations across the globe. Yield of similar 3xfootprint Pure has designed a unique multi-ponic* growing system that combines the bestpractices of hydroponics, aquaponics, and aeroponics, with world-class commercial agriculture methodologies. Our automated system is capable of growing more plants in less time, without the use of herbicides or pesticides. *Patent pending The Root Is The Heart: Closed-loop systems allow us to tailor the biochemistry and nutrients to deliver exactly what the roots need at every stage for optimal growth. Best In Class: Targeted spectrum LED lighting systems ensure the plant expends all its energy on growing the purest, most abundant high-grade flower. More Canopy, Less Space: Vertical farming enables us to grow multiple tiers of canopy, exponentially increasing potential yield from the same square footage. Individual Attention: Utilizing controlled-growth environments, every plant is meticulously cared for and monitored throughout its life cycle to ensure optimal growth.

9 TSX.V:PURE OTC:PRCNF Consumer Brand Targeting Medical & Wellness Targeted branding in the medical and wellness segments Partnerships with clinics, health care professionals, and patient advocacy groups nation-wide R&D driven - investing in accelerated pharma drug development with JVs with large pharma and academia Client Experience is at the top of our list of priorities Driven by Trust by uncompromising Quality and Product Consistency and leveraging GMP and ISO standards Customer-Shopper-Consumer centric branding strategies to create a market segment focused lifestyle brand

10 TSX.V:PURE OTC:PRCNF Flagship International Facility Sativa Nativa S.A.S. - Colombia* Assuming Pure Global s 75% interest in Sativa Nativa, PURE will have total production capacity of 132,000+ kg, by Q1 2020 across a combined 904,000 sq. ft. in Canada & Colombia* Sativa Nativa S.A.S. - Signed binding LOI with Avicanna Inc. ("Avicanna") to obtain a 60% interest in Sativa Nativa S.A.S. ("Sativa Nativa"), with an option to increase PURE s interest to 75%. Issued Licenses - Sativa Nativa has been issued licenses for the cultivation of psychoactive and non-psychoactive cannabis, and for the manufacturing of cannabis derivatives by the Colombian Ministry of Justice and Colombian Ministry of Health Large land package - Includes up to 28 hectares (69 acres) of agriculture land with existing irrigation and infrastructure, situated at the foothills of the Sierra Nevada mountains, in Santa Marta, Colombia, ideal climate for lowest input costs possible Leading state-of-art greenhouse - 100,000 sq ft. GAP greenhouse situated on land package nearing completion, along with a 20,000 sq ft. GMP indoor facility, and have commenced design of an additional 1,000,000 sq ft. leading state-of-the-art greenhouse using advanced growing technologies for greater yields. Fraction of Capital and Operational costs versus Canadian producers, ideal for global export and long-term access to high-quality low-cost inputs *Assumes completion of binding LOI signed with Avicanna Inc, previously announced August 15, 2018

11 TSX.V:PURE OTC:PRCNF The Colombian Advantage Comprehensive Legal Framework - Regulations already in place for the export of cannabis (to EU 700M people and South Americas 400M people) and access to Colombia s 50M population. Colombia has secured cannabis export quota of 40.5 tons, representing 44% of 2018 s global demand Santa Marta World-Leading Agricultural Region - Santa Marta, Colombia provides the ideal cannabis production climate with 12 hours of light per day, yearround, allowing for 4 cultivation cycles per year, with ideal humidity at the foothills of the Sierra Nevada Mountains Quality Work Force - Strong and relatively low-wage workforce, access to private water wells, attractive energy costs, international ports, all are ideal conditions for economical cannabis cultivation, processing, and global export Cost Competitive advantage - Cultivation costs in Colombia compared to Canadian-based facilities will result in a cost per gram to PURE that provides significant leverage in its Colombian-based production destined for international export Strong Partnership with Avicanna - Provides access with Sativa Nativa to a comprehensive program of over 80 registered and characterized genetics representing one of the largest genetic banks in Latin America

12 TSX.V:PURE OTC:PRCNF A Quicker Path To Revenue With Concentrates The foundation for all medical applications and high-margin recreational products is cannabis concentrates. Our Phase 1 facilities are equipped with GMP standard clean rooms to produce and package innovative and proprietary extraction formulations for retail and medical markets. Dried Flower Cannabis Oils Soft Gels & Capsules Seedlings & Clones Vape Pen Cartridges Canadian Oil Sales International Oil Exports 30% GROWTH 300% INCREASE Topicals Sublingual Strip/Spray Transdermal Patch Edibles & Beverages Wellness Products Quarter over quarter From 2016 2017

13 TSX.V:PURE OTC:PRCNF Pure Patient Driven Solutions Our core focus on purity puts patient wellbeing at the centre of everything we do. Over the long term, we believe consumers will develop a better understanding of cannabis and be able to segment products based on perceived quality. As a result, although a strong brand may encourage initial trial, there must be perceived product quality and a consistent user experience to validate the brand and generate repeat purchases. BMO, Canada Leads the Global Cannabis Paradigm Shift, May 2018 1. 2. 3. 4. Quality First Our multi-ponic vertical farm is rooted in world-class commercial horticulture and delivers uncompromising quality and consistency. Exceptional Service Continuous feedback loops curate a deep understanding of our patients needs, and ensure satisfaction and engagement during every interaction. Clinic Partnerships Utilizing proven formulas for rapid patient acquisition leveraging alliances with clinics and referring physicians to capture market share and increase loyalty. Innovative Marketin g A bold, multi-faceted brand strategy creates immediate demand and opens up new patient acquisition touch-points across growing customer verticals

14 TSX.V:PURE OTC:PRCNF Management Malay Panchal, RPh, BScPhm Founder & CEO, Board Member A seasoned serial-entrepreneur with 20+ years experience in pharma B2B technology, retail and mail-order pharmacy, pharma branding and clinical trials. Nader Gheshlaghi, PhD, MSc VP, Production, PureSinse Inc. World renowned Plant Genetics & Pathologist, has managed largescale grow operations for hundreds of medical and commercial plant varieties around the world with international industry and academic awards, and many patents. Stephen Pynn VP, Corporate Development Significant experience in Capital Markets and Corporate Finance with a focus primarily on the cannabis sector s financings and public offerings. Former cannabis Capital Markets expert at PI Financial Corp. participated in over $800M of financings. Bhup Gosain, CPA, CA, CPA (IL) Chief Financial Officer 30+ years experience in tax and business advisory services in a variety of sectors including technology, life sciences, biotechnology, natural resources and pharma. Former senior management at Deloitte and partner at MNP. Trupti P. Smit, LLB Director of Corporate and Legal Affairs 15 years as cross border transactions, corporate, intellectual property, commercial and international tax lawyer; Legal Counsel at RBC International Tax and Transfer Pricing. Vik Chopra, MBA VP, IT and Business Operations Program delivery expert with 20 years of experience at tier 1 advertising and technology companies. Strong understanding of agile project management methodology, business and IT operations. Held senior positions at Y&R, Kobo and Postmedia Network.. Michael Lavergne Head of Supply Chain Hands-on sustainable supply chain and operations professional with 20 years of multinational experience in fast-moving consumer goods (FMCG) / retail. Former VP Global Supply Chain Shoppers Drug Mart, held senior positions at Joe Fresh and Walmart. Vishwas Sawant, MBA General Manager, PureSinse 30 years of global experience in heavy engineering manufacturing, agribusiness, retail and IT. Former CEO, Farmers Co-op, India, 55M CAD revenue, 1200 employees.

15 TSX.V:PURE OTC:PRCNF Board Malay Panchal, RPh, BScPhm Founder & CEO, Board Member A seasoned serial-entrepreneur with 20+ years experience in pharma B2B technology, retail and mail-order pharmacy, pharma branding and clinical trials. Dr. Chandra Panchal, PhD Chairman Distinguished resume includes Director for MaRS Innovation, senior scientist at John Labatt Ltd., and Chairman, President and CEO at Procyon Biopharma Inc. CEO of Axelon pharma, Director in several public companies. Jane Pagel, MSc Board Member Retired executive with extensive experience, previously held positions as the President & CEO of the Ontario Clean Water Agency, and Director of Research & Technology at the Ministry of the Environment. Brian O Neill, BSc, LLB Board Member Nearly a decade in the practice of law at a leading national law firm, focused on M&A, corporate reorganizations, corporate finance, intellectual property, and commercial transactions. BSc (Hon) Molecular Genetics, 10 years at McCarthy Tetrault LLP. Albert Beraldo, CPA, CA Board Member More than 30 years experience in various senior leadership roles within the pharmaceutical and biotechnology industry, including Founder & CEO of Alveda Pharmaceuticals Inc.

16 TSX.V:PURE OTC:PRCNF Capital Markets Advisors Jeffrey Zicherman Eventus Capital Founder and CEO of a leading investment bank based in Toronto, Canada. Jeff has led or been directly involved in raising over $600 million in equity for numerous public companies in recent years, including several cannabis mandates. Aaron Salz Stoic Advisory Founder and CEO of a pioneering financial advisory firm focused on the cannabis industry. Aaron has been directly involved in over $1.5 billion of M&A transactions in the cannabis industry alone and advised numerous CEOs and boards of directors in the sector. Industry Advisors Trina Fraser Brazeau Seller Law Paul Sparkes Norris Point Capital Jim Youmans Rx Samples Solutions USA Dr. Matthew D. Burnstein B.Sc., M.D. Appletree Medical Group The foremost cannabis policy and regulatory expert in the industry, Trina is actively working with Pure Global on regulatory affairs and licensing applications. Former senior aid to two Premiers, Director of Operations to Prime Minister Chretien, former LCBO board member; advising on market penetration strategies. 40+ years experience in corporate pharma. Former CMO Glaxo global, Former President Sandoz Global, Former COO Novartis Global advising on medical branding, sales and market strategies. Over 35 years of practice as a family physician. Certified Medical Review Officer, trained to develop workplace drug and alcohol programs, as well as interpret drug tests.

17 TSX.V:PURE OTC:PRCNF Pure Capital Structure TSX.V:PURE OTC:PRCNF $0.34/share* Market cap $50M Issued and outstanding 148.2M Warrants and options 34.6M Fully diluted 182.8M Cash $11.2M** Debt $0** Management and Insider Ownership - 21% *As at September 4, 2018 ** As at July 11, 2018

18 TSX.V:PURE OTC:PRCNF Canadian & Colombian Comps Market Cap Range: $37M-$13.1B Average Market Cap - $1.12B Median Market Cap - $217M Pure Global Cannabis (TSX.V:PURE) has exposure to 2 Production Licenses in Canada & Colombia* $50M market cap - 132,000+ kg production capacity for Q1 2020 over 904,000 sq ft. - fully funded * Assumes completion of binding LOI signed with Avicanna Inc, previously announced August 15, 2018 Source: Company Reports, Thomson Eikon, SEDAR, Analyst Estimates, Basic Market Capitalization as of August 31, 2018

pureglobal.com info@pureglobal.com